Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
TuHURA Biosciences ( (HURA) ) has shared an update.
On June 2, 2025, TuHURA Biosciences announced a $12.6 million private placement agreement with investors, involving the issuance of 4.76 million shares and warrants. The funds will support the company’s merger with Kineta, Inc., the initiation of a Phase 3 trial for IFx-2.0, and the advancement of other pipeline projects. The transaction, structured in tranches, is contingent on milestones such as FDA clearance and merger conditions. This financing is expected to bolster TuHURA’s strategic initiatives in cancer immunotherapy, enhancing its market position and operational capabilities.
The most recent analyst rating on (HURA) stock is a Buy with a $12.00 price target. To see the full list of analyst forecasts on TuHURA Biosciences stock, see the HURA Stock Forecast page.
Spark’s Take on HURA Stock
According to Spark, TipRanks’ AI Analyst, HURA is a Underperform.
TuHURA Biosciences faces significant financial instability with no revenue and increasing net losses, heavily weighing down its overall score. Despite technical analysis showing some short-term momentum, the company’s poor valuation metrics and reliance on financing present substantial risks. The positive corporate event of a new board appointment offers some future potential but is not enough to offset the current challenges.
To see Spark’s full report on HURA stock, click here.
More about TuHURA Biosciences
TuHURA Biosciences, Inc. is a Phase 3 immuno-oncology company focused on developing novel technologies to overcome primary and acquired resistance to cancer immunotherapy. The company is advancing its lead product, IFx-2.0, designed to enhance the effectiveness of checkpoint inhibitors, and is preparing for a Phase 3 trial in advanced or metastatic Merkel Cell Carcinoma. TuHURA is also leveraging its Delta Opioid Receptor technology to develop innovative antibody drug conjugates targeting immune-suppressing cells.
Average Trading Volume: 188,799
Technical Sentiment Signal: Strong Sell
Current Market Cap: $123.2M
See more data about HURA stock on TipRanks’ Stock Analysis page.